Compare AEVA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | TLSI |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 270.2M |
| IPO Year | 2020 | 2020 |
| Metric | AEVA | TLSI |
|---|---|---|
| Price | $15.65 | $4.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $26.50 | $7.00 |
| AVG Volume (30 Days) | ★ 1.3M | 231.9K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | $85.37 | $35.45 |
| Revenue Next Year | $132.72 | $37.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $8.83 | $2.20 |
| 52 Week High | $31.30 | $7.95 |
| Indicator | AEVA | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 35.40 |
| Support Level | $13.77 | $4.28 |
| Resistance Level | $16.67 | $4.47 |
| Average True Range (ATR) | 0.83 | 0.36 |
| MACD | 0.25 | -0.04 |
| Stochastic Oscillator | 63.84 | 2.32 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.